News http://www.xendo.com/news.rss en Immulite 2000 Analyzer http://www.xendo.com/news/4793/ http://www.xendo.com/news/4793/ Fri, 31 Oct 2008 14:00:00 +0100 Immunogenicity analysis and multiplex biomarker assays with new ECL equipment at Xendo http://www.xendo.com/news/4668/ http://www.xendo.com/news/4668/ Tue, 29 Jul 2008 15:00:00 +0200 Full clinical research services now offered http://www.xendo.com/news/4153/ http://www.xendo.com/news/4153/ Fri, 21 Dec 2007 08:30:00 +0100 Xendo's Bioanalysis and Drug Metabolism introduces new LIMS http://www.xendo.com/news/3858/ http://www.xendo.com/news/3858/ Tue, 06 Nov 2007 15:00:00 +0100 Disposables Reach Out to New Markets http://www.xendo.com/news/3760/ http://www.xendo.com/news/3760/ Mon, 08 Oct 2007 09:00:00 +0200 TI Pharma project on metabolic stability of NCE's takes off http://www.xendo.com/news/3631/ http://www.xendo.com/news/3631/ Mon, 17 Sep 2007 14:00:00 +0200 Xendo joins the Ride for the Roses http://www.xendo.com/news/3610/ http://www.xendo.com/news/3610/ Fri, 07 Sep 2007 10:30:00 +0200 Xendo CTM's director interviewed by C2W http://www.xendo.com/news/3607/ Interview with Ard Tijsterman, Managing Director of Xendo Clinical Trial Material http://www.xendo.com/news/3607/ Fri, 31 Aug 2007 13:30:00 +0200 New Managing Director in Denmark http://www.xendo.com/news/3299/ As of the 1st of June 2007, Xendo Pharma Service A/S in Denmark has appointed Klaus Snej Jensen, as new Managing Director. Klaus will focus on the further development of the Xendo consulting capabilities in Medicon Valley as well as the general management of the Danish Division. http://www.xendo.com/news/3299/ Thu, 21 Jun 2007 12:00:00 +0200 The bisphosphonates bioanalytical challenge – Xendo’s answer: the risedronate case http://www.xendo.com/news/3228/ The bisphosphonates bioanalytical challenge – Xendo’s answer: the risedronate case http://www.xendo.com/news/3228/ Mon, 07 May 2007 13:30:00 +0200 Focus Scandinavian activities http://www.xendo.com/news/3182/ http://www.xendo.com/news/3182/ Wed, 25 Apr 2007 10:00:00 +0200 Xendo CTM, a new life science company in The Netherlands http://www.xendo.com/news/3091/ CMO for low cost GMP manufacturing of recombinant proteins and monoclonal antibodies for phase I and phase II clinical trials http://www.xendo.com/news/3091/ Thu, 05 Apr 2007 08:30:00 +0200 Business Management services expanded http://www.xendo.com/news/2859/ http://www.xendo.com/news/2859/ Mon, 26 Mar 2007 20:30:00 +0200 Clinical pharmacology of chiral compounds – an expertise of Xendo http://www.xendo.com/news/2839/ Xendo Drug Development B.V. is a leading participant within the Ultimate Chiral Technologies consortium (UCT). This consortium focuses on further developing expertise in chiral science and technology, in combination with DSM Pharma Chemicals, Syncom and two major Dutch Universities (Groningen and Nijmegen). http://www.xendo.com/news/2839/ Mon, 19 Mar 2007 16:30:00 +0100 GMP status van Nederlandse ziekenhuizen http://www.xendo.com/news/2780/ http://www.xendo.com/news/2780/ Fri, 09 Mar 2007 00:00:00 +0100 Xendo Newsletter special edition on bioanalysis and biomarkers - out now! http://www.xendo.com/news/2528/ http://www.xendo.com/news/2528/ Wed, 10 Jan 2007 00:00:00 +0100 Xendo conducts human microdosing (human phase 0) study for Biofrontera AG http://www.xendo.com/news/2526/ http://www.xendo.com/news/2526/ Wed, 10 Jan 2007 00:00:00 +0100 On-line clinical studies – LPS challenge testing http://www.xendo.com/news/2495/ http://www.xendo.com/news/2495/ Fri, 22 Dec 2006 00:00:00 +0100 On-line clinical studies – full integration of CPrU and bioanalysis http://www.xendo.com/news/1177/ http://www.xendo.com/news/1177/ Mon, 04 Dec 2006 00:00:00 +0100 Biotech News interview with Koos Koops and Ard Tijsterman http://www.xendo.com/news/731/ http://www.xendo.com/news/731/ Wed, 15 Nov 2006 00:00:00 +0100 Xendo partner in Top Institute Pharma http://www.xendo.com/news/721/ http://www.xendo.com/news/721/ Wed, 15 Nov 2006 00:00:00 +0100